These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2654665)

  • 1. Effect of oxoplatinum and CBDCA on renal functions in rats.
    Láznícková A; Semecký V; Láznícek M; Zubr V; Koksál J; Kvĕtina J
    Neoplasma; 1989; 36(2):161-9. PubMed ID: 2654665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes].
    Kimura S; Nakajima Y; Hasegawa S; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1989 Apr; 80(4):517-25. PubMed ID: 2664296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
    Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
    Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of second generation platinum cytostatics on mammalian cell proliferation.
    Keprtová J; Smutná A; Minárová E; Vrána O
    Neoplasma; 1990; 37(2):121-9. PubMed ID: 2188163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.
    Meijer S; Sleijfer DT; Mulder NH; Sluiter WJ; Marrink J; Koops HS; Brouwers TM; Oldhoff J; van der Hem GK; Mandema E
    Cancer; 1983 Jun; 51(11):2035-40. PubMed ID: 6340821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental studies on the pharmacokinetics and nephrotoxicity of carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) in rats.
    Ueda T; Yasumasu T; Uozumi J
    J Toxicol Sci; 1991 Aug; 16(3):101-9. PubMed ID: 1942134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
    Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H
    Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical toxicology of platinum analogues in dogs.
    Lelieveld P; van der Vijgh WJ; van Velzen D
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1147-54. PubMed ID: 3308482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical studies identifying carboplatin as a viable cisplatin alternative.
    Harrap KR
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():21-33. PubMed ID: 3910219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics of the action of cisplatin and cycloplatam on the rat kidney].
    Natochin IuV; Reznik LV; Brovtsyn VK; Ivanov VB; Miazina EM; Chel'tsov PA; Shakhmatova EI
    Biull Eksp Biol Med; 1989 Jul; 108(7):52-4. PubMed ID: 2804301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.
    Láznícková A; Láznícek M; Kvĕtina J; Drobník J
    Cancer Chemother Pharmacol; 1986; 17(2):133-6. PubMed ID: 3521926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG; Rarey KE; Dolan DF; Abrams G; Litterst CJ; Sheridan C
    Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
    Prajda N; Kralovánszky J; Gal F; Kiss F; Kerpel-Fronius S
    In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effects of tetraplatin and cisplatin on renal function and gentamicin pharmacology in rats.
    Engineer MS; Brown NS; Ho DH; Newman RA; Bulger RE
    Toxicology; 1989 Dec; 59(2):151-62. PubMed ID: 2588264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute and subacute toxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in laboratory rodents].
    Härtl A; Güttner J; Horn U; Jelinek F; Stöckel U; Schröer HP; Hoffmann H
    Arch Geschwulstforsch; 1989; 59(4):239-44. PubMed ID: 2640563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
    Siddik ZH; Newell DR; Boxall FE; Harrap KR
    Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of platinum drugs on the radiation response of rat kidneys.
    van Rongen E; Kuijpers WC; Baten-Wittwer A
    Radiother Oncol; 1994 May; 31(2):138-50. PubMed ID: 8066193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and cumulative effects of carboplatin on renal function.
    Sleijfer DT; Smit EF; Meijer S; Mulder NH; Postmus PE
    Br J Cancer; 1989 Jul; 60(1):116-20. PubMed ID: 2679841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
    Sharma H; Thatcher N; Baer J; Zaki A; Smith A; McAucliffe CA; Crowther D; Owens S; Fox BW
    Cancer Chemother Pharmacol; 1983; 11(1):5-7. PubMed ID: 6349844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.